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with luminal A, only triple-negative breast cancer was 
significantly related with decreased 5-year OS and DFS rate 
(p value <0.001, respectively). 
 
Conclusion: Non-pCR group showed significantly decreased 5-
year OS and DFS rates than pCR group, especially in triple 
negative and HER2-enriched breast cancer patients. In the 
case of pCR, there was no difference in survival rates 
regardless of molecular subtypes. While a significant 
difference between survival rates and molecular subtypes 
was found in the patients who failed to attain pCR. Compared 
to luminal A, only triple-negative subtype was associated 
with distinctly decreased 5-year OS and DFS rates. 
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Purpose or Objective: Comparative outcome data after 
intraoperative radiotherapy (IORT) and external beam 
radiotherapy (EBRT) for breast cancer at >5ys median follow-
up are rare. We present a large, mature single-institution 
matched-pair-comparison reporting survival and relapse-rates 
in patients treated with either modality. 
 
Material and Methods: Complete datasets for 258 IORT-pts 
treated between 2000 and 2010 were matched with 258pts 
postoperatively treated with EBRT by age/histology/tumor 
size, grading/lymph-node-status/hormone-receptors/type of 
adjuvant therapy/surgical margins/treatment-date. EBRT was 
performed with 2 tangential fields to whole breast 
(50Gy/25fractions) and with 9-12MeV direct-electron-field-
boosts to tumor bed (10-16Gy/5-8 fractions). A non-
dedicated Linac (green-line-setup) with direct 8-12MeV 
electron fields (21Gy prescribed to 90%-isodose) delivered 
IORT. Relapse at surgical intervention site was classified as 
true local recurrence(LR). All recurrences in the treated 
breast (any quadrant) were classified as Ipsilateral 
Recurrence(IR). 
 
Results: Median follow-up was 79 months (12-156) for both 
groups. IR were 11 after IORT and 6 after EBRT. LR for IORT 
and EBRT groups were 8 and 3, respectively. Cumulative 
incidence of IR at 5ys were 2.3%(IORT) and 1.4%(EBRT), 
(p=n.s., HR 1.8 CI 95% 0.69-5). Cumulative incidence of LR at 
5ys was 1.5%(IORT) and 0.8%(EBRT), (p=n.s., HR 3.1 CI 95% 
0.8-11.3) Overall survival(OS) at 3/5ys was 
98.8%/96.1%(IORT) and 98.8%/95.3%(EBRT), (n.s.). Disease-
free survival(DFS) at 3/5 ys was 97.2%/93.2%(IORT) and 
98%/93.5%(EBRT) (n.s). Between IORT and EBRT, no 
differences in non-breast-cancer-related-deaths or second-
cancer-incidence were recorded. When analyzed according to 
ASTRO-criteria for accelerated-partial-breast-
irradiation(APBI), outcome was better in the APBI-suitable 
group than in the entire cohort and the APBI-unsuitable 
group. The IR at 5ys for APBI-suitable/cautionary/unsuitable 
were 0%/2,7%/8% respectively 
 
Conclusion: In line with published randomized-trial-data, IR-
rate was higher after IORT than after EBRT if no stringent 
patient selection was performed. Non-breast-cancer-
mortality and second-cancer-incidence did not differ 
between IORT and EBRT. In patients suitable for APBI 
according to ASTRO-criteria, similar IR-, LR- and OS-data 
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Purpose or Objective: The current standard treatment for 
early breast cancer is a combination of conserving surgery 
and endocrine therapy or that of endocrine therapy and 
chemotherapy or chemotherapy alone. Even after remarkable 
technical advances in breast cancer surgery, physical and 
mental invasion for patients after surgery is a problem to be 
solved. Also patients of dying from breast cancer for surgery 
denial exist. In this study, we evaluated the usefulness and 
safety of novel non-operative enzyme-targeting 
radiosensitization: Kochi Oxydol-Radiation Therapy for 
Unresectable Carcinoma, type II (KORTUC II) with endocrine 
therapy for stage I and II breast cancer.  
 
Material and Methods: From October 2006 to September 
2013, radiation therapy was performed for 44 women 
(median age 63years ranging from 37 to 88 years) of breast 
cancer (Stage 0; n=2, Stage I; n=19, and stage II; n=23). All 
patients refused both surgery and systemic chemotherapy. 
Radiation therapy performed was 44Gy/ 16fr/ 3.5W for total 
breast with field-in-field technique, then electron beam 
boost 9Gy / 3fr / 3days was added to the tumor bed. We 
injected the sensitizer (0.5% hydrogen peroxide solution + 
0.83% sodium hyaluronate) under ultrasound guidance, before 
radiation therapy twice a week. Median follow-up period was 
51 months (21-104 months). After the treatment, both PET-
CT and breast MR were performed every year.  
 
Results: About adverse event no skin symptoms more than 
grade3 was observed Beauty effect was excellent or good in 
all cases. Local recurrence was seen in only 2 case (4.5%). 
Distant metastasis was not observed. Only one patient died 
from other disease.  
 
Conclusion: From the results of this study it was suggested 
that KORTUC II followed by endocine therapy is effective and 
safe as the therapy for stage I and II breast cancer. 
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Purpose or Objective: Randomized trials have established 
the role of hypofractionated radiation therapy (HFRT) in 
early breast cancer. HFRT allows for less costly and more 
accessible treatment. However, there is paucity of data for 
HFRT in locally advanced breast cancer (LABC). We report 
the impact of HFRT in unselected breast cancer patients (all 
stages except metastatic, both BCS /MRM) and compared 
with CFRT for any differences in outcomes. 
 
Material and Methods: 463 patients of BCS/MRM treated 
between Jan’08 and July’13 with CFRT (50Gy/ 25fr) or 
HFRT(42.4Gy/16 fr or 40Gy/15) to the breast/chest wall (CW) 
± SCF ± Ax, treated in 2 time periods were retrospectively 
reviewed. RT was given by direct electron field/ bitangential 
photons to the CW and by latter to the breast. SCF ± Ax RT 
was given by enface photons (when indicated). All patients of 
BCS received a tumor bed boost. Statistical analysis to 
compare the 2 groups for survival outcomes, was done in 
Sept’15. The primary endpoint was to compare the 
differences in loco regional recurrences (LRR) between the 2 
groups. 
 
